Interesting data from Phase 2 study #COMRADE at #ESMO26: Early on-treatment #ctDNA may help identify patients at risk of progression after just one cycle of #radium223. Possibly one more step toward biomarker-guided, adaptive radiopharmaceutical therapy.
We are getting more and more evidence about a potential key prognostic role of ctDNA also in #ProstateCancer including evidence that it may be used as a guide for treatment modulation - it will be most important now to prospectively include ctDNA in more trials and further validate it #mCRPC #RLT #Olaparib #radium223 @urotoday @oncodaily @OncoDailyGU @DrRanaMcKay
25 views · 0 likes · 0 reposts · 0 replies
Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.orgLongitudinal ctDNA Tumor Fraction in Bone-Dominant #mCRPC Treated with Radium-223 ± Olaparib: Results from the Phase 2 COMRADE Trial. Presented by @DrRanaMcKay @UCSanDiego. #ESMO26 written coverage by @rksayyid @UAUrology > https://bit.ly/4eAzxVR #ProstateCancer #PrecisionOncology @myESMO在 X 查看被引用的帖子
Source: Sabine D. Brookman-May · x.com